Jeito
Jeito is an independent biopharma investment firm focused principally on clinical-stage companies developing therapies for severe diseases and unmet medical needs.
- Healthcare and biotechnology venture capital investor
- Healthcare & BioTech Venture Capital
- Tier III
Overview
Jeito is an independent biopharma investment firm focused principally on clinical-stage companies developing therapies for severe diseases and unmet medical needs. Its multidisciplinary team spans drug development, regulation, intellectual property, manufacturing, commercial strategy, and market access.
The firm’s institutional position strengthened materially in 2026 with the closing of Jeito II above €1 billion. That capital allows it to provide substantial financing through successive clinical-development milestones and to support European companies with global ambitions. Within The Economy Wiki, the institution is connected to the Healthcare & Biotechnology Venture Capital market category.
Firm facts
| Institution | Jeito |
| Type | Healthcare and biotechnology venture capital investor |
| Headquarters | Paris, France |
| Founded | 2018 |
| Primary ranking focus | Healthcare & BioTech Venture Capital |
| Highest 2026 tier | Tier III |
Activities and investment capabilities
Jeito operates within life-sciences innovation, clinical development and healthcare company building. Its category-specific capabilities are summarized below.
Life-sciences investing
Capital for therapeutics, diagnostics, medical devices and research platforms.
Clinical development
Support across scientific validation, trials, regulation and commercialization.
Healthcare innovation
Investment in care delivery, health technology and data-enabled medical businesses.
Strategy and market coverage
Stage and strategy coverage
Company formation through growth; translational research; clinical and commercial financing
Sector and market coverage
Biotechnology; therapeutics; diagnostics; medtech; digital health and healthcare services
Market position
Jeito fits Tier III because its history remains short relative to the established Tier II firms and its emphasis is later-stage biopharma rather than broad venture formation. Its scale, specialist team, independence, and recent momentum make it one of the strongest new inclusions.
Jeito is assessed within the Healthcare & Biotechnology Venture Capital framework. For wider market context, see The Mid-Market Advantage in Healthcare Private Equity.
Competitive context
Jeito is recognized Tier III in Top 30 Healthcare & BioTech Venture Capital 2026. The rankings compare institutions by market relevance, investment or operating capability, sector and stage expertise, institutional credibility and current activity. Comparable links support navigation and do not imply that every institution competes for every company, fund commitment or transaction.
Leadership and governance
Leadership, investment-committee composition and operating resources may change over time. Current information should be confirmed through the institution’s official website.
| Leadership area | Current source |
|---|---|
| Investment and operating leadership | Current team and governance information |
Corporate and public information
This profile refers to Jeito as the public-facing organization. Individual funds, management companies, advisers, lending entities, broker-dealers and regulated affiliates may use separate legal names across jurisdictions.
Corporate and disclosure information
| Organization | Jeito |
| Headquarters | Paris, France |
| Public website | www.jeito.life |
| Profile basis | Public institutional information and Capital Ranking editorial research |
Ranking recognition
Related Economy analysis
Selected Economy Markets articles provide context for the venture, financing, diligence and private-market themes relevant to this institution:
- The Mid-Market Advantage in Healthcare Private Equity
- Growth Equity vs Venture Capital and Buyouts: Key Differences
- Private Equity Technology Due Diligence in the AI Era
